Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2008
03/13/2008US20080064685 Pyrrolo[2,1-C][1,4]benzodiazepine hybrids and a process for the preparation thereof
03/13/2008US20080064684 Sub-type selective serotonin receptor agonists; antidepressants; schizophrenia, Alzheimer's Disease, Parkinson's Disease; alkylation or amidation of the heterocyclylbenzazole with an alkylhalide or acylhalide
03/13/2008US20080064683 Oral or intraveinous administration of 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; ELISA analysis; angiogenesis inhibitors; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration
03/13/2008US20080064682 1,5-diaryl-3-N-heterocycylcarbonylpyrazoles; antiagglomerants that do not inhibit cyclooxygenases; antiischemic agents
03/13/2008US20080064681 4-halo-5-(1-imidazolidinyl, 1-pyrazinyl, 1-(1,4-diazepinyl), or 1-(1,4-diazocinyl)sulfonyl)isoquinoline eye drops decrease intraocular pressure; rho-kinase inhibitors
03/13/2008US20080064680 Methods for Diagnosis and Treatment of Cancer
03/13/2008US20080064679 Water Soluble Cannabinoids
03/13/2008US20080064678 N-tert-Butyl-2-[3-(4-fluoro-3-methoxyphenyl)-1-oxo-7-(3-pyrrolidin-1-ylpropoxy)-1H-isoquinolin-2-yl]acetamide; 2-[3-(3-Chlorophenyl)-7-((S)-2-methyl-3-pyrrolidin-1-ylpropoxy)-1-oxo-1H-isoquinolin-2-yl]-N-isopropylacetamide; antidepressants; hypothalamo-pituitary-adrenal axis modulators
03/13/2008US20080064677 S1P receptor modulating compounds and use thereof
03/13/2008US20080064676 Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity
03/13/2008US20080064675 And crystal growth inhibitors for drugs, pesticides, herbicides, proteins, amino acids, vitamins, or antibiotics, preferably modafinil, drospirenone, eplerenone, raloxifene or anetholtrithione; vanillin, ethylvanillin, trans-anethole, or coumarin; nontoxic
03/13/2008US20080064674 Pharmaceutical Compositions
03/13/2008US20080064673 Cyanopyrrole-phenyl amide progesterone receptor modulators and uses thereof
03/13/2008US20080064672 Compositions containing topical active agents and pentyleneglycol
03/13/2008US20080064671 Combinations containing a 4-acylaminopyridine derivative
03/13/2008US20080064670 Including Premenstrual Dysphoric Disorder; administering ethinyl estradiol and levonorgestrel in combination for 81 to 89 consecutive days followed by only ethinyl estradiol for 7 consecutive days and an antidepressant intermittantly administered
03/13/2008US20080064669 Calcipotriene anhydrate, betamethasone dipropionate and at least one of a triglyceride, sorbitan, sorbitan fatty ester, cetearyl glucoside, polyethylene glycol-n sorbitan stearate, acrylamide-sodium acryloyldimethyl taurate copolymer; topical treatment for psoriasis; improved storage stability
03/13/2008US20080064668 Carbon 20 is substituted with methyl or cyclopropyl, carbon 16 is a single or double bond, and carbon 23 is a single, double, or triple bond; side effect reduction; vitamin deficiency; anticarcinogenic antiarthritic agents; immunotherapy; metabolic disorders; gene expression inhibition of ILT3
03/13/2008US20080064667 5,8-bis(dimethylamino)-2-(2,2-diphenylvinyl)-9,11a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide; effective against minocycline- and tetracycline-resistant bacteria
03/13/2008US20080064666 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
03/13/2008US20080064665 Combination approaches to cancer treatment
03/13/2008US20080064664 Foods or feeds containing a sphingomyelin derived from cow milk; moisturizers; improved smoothness; wrinkle resistance
03/13/2008US20080064662 Agonists having a biphenyl moiety in combination with an amide linkage at the core of the structure enhances selectivity for S1P1 receptor without causing hypotension or bradycardia; transplant rejection, autoimmune diseases; 2-Amino-N-[4-(biphenyl-4-yloxy)-phenyl]3-hydroxy-2-methyl-propionamide
03/13/2008US20080064661 Dihydroxyl compounds and compositions for cholesterol management and related uses
03/13/2008US20080064660 Modulation of Inflammation Related to Columnar Epithelia
03/13/2008US20080064659 Reacting Boc-Leu-OMe with dimethyl methylphosphonate treated with tert-butyllithium, formaldehyde and potassium oxide to produce the hydroxymethyl-substituted enone; multi-step peptide coupling to form dihydroeponemycin analogues; angiogenesis inhibitors; Alzheimer's and Huntington's Diseases
03/13/2008US20080064658 Use of Isomaltooligosaccharides to Decrease Abdominal Fat
03/13/2008US20080064657 For birds and mammals by oral administration; probiotics; non-competitive inhibitors of alpha -glucosidase; fermenting sucrose in the presence of maltose
03/13/2008US20080064656 Improvement of intestinal barrier integrity
03/13/2008US20080064655 Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B
03/13/2008US20080064654 Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
03/13/2008US20080064653 A2A receptor agonists for the central nervous system; antiinflammatory agents; 2,7-disubstituted-5-amino-pyrazolo[4,3-e]-[1,2,4]-triazolo[1,5-c]pyrimidines, mefloquine, 8-(3-chlorostyryl)caffeine, 3,7,8-trisubstituted-1-propargyl-xanthines; 2,5-disubstituted-7-amino-[1,2,4]triazolo[1,5-a][1,3,5]triazines
03/13/2008US20080064652 Without inducing hypertriglyceridemia; injecting a therapeutic apoE nucleic acid that expresses a naturally-occurring apoE protein, associated with a liposome directly into the liver; the nucleic acid is a recombinant adeno-associated vector, a lentiviral, herpes viral, or retroviral vector
03/13/2008US20080064651 A 21-base antisense oligonucleotide which inhibits gene expression of testosterone-repressed prostate message-2 by tumor cells; prostate and renal cell cancer; enhanced chemosensitivity, hormone and radiation sensitivities
03/13/2008US20080064650 Therapeutic uses of inhibitors of RTP801L
03/13/2008US20080064648 Methods and Compositions Relating to Lipid Accumulation
03/13/2008US20080064647 A polyvalent multimeric complex formed from a plurality of circularly permuted chimeric pRNA molecules, each carrying a stabilized biologically active moiety; degradation resistant stabilized ribozyme is correctly folded such that it remains intracellularly active
03/13/2008US20080064646 Lactobacillus Fermentum N-Desoxyribosyl Transferases and the Use Thereof for Enzymatic Synthesis of 2', 3' - Didesoxynucleosides and 2',3'- Didehydro-2',3'- Didesoxynucleosides
03/13/2008US20080064645 A carbohydrate linked to a fluorophore through a 2-amido-2-(1-hydroxyalkyl)ethoxy linkage; inhibition of caveolar endocytosis, plasma membrane microdomain formation, virus binding and infection, transmembrane signaling, and integrin function in cells; anticarcinogenic and antiinflammatory agents
03/13/2008US20080064640 Particularly drugs and cosmetic agents; ethoxylated meadowform oil having between 10 and 19 ethoxy units, and the delivered agent, especially analgesics, antiinflammatory agents or antiwrinkle agents; improved penetration and bioavailability
03/13/2008US20080064602 Herbicide, pesticide, parasiticide or miticide milled together with calcium carbonate, dispersants, surfactants and disintegrants in a water-soluble carrier chosen from acrylic ester-acrylamide copolymer, polyacrylic acid or crosslinked polysodium acrylate; gel or pastes; improved ease of application
03/13/2008US20080063730 Methods for prophylactic and therapeutic nutritional supplementation
03/13/2008US20080063726 Micronized fenofibrate; polyvinylpyrrolidone, polyvinyl alcohol, hydroxypropylcellulose hydrophilic polymer; sodium lauryl sulfate, monooleate, monolaurate, monopalmitate surfactant; starch, colloidal silica, cross-linked polyvinyl pyrrolidone inert hydrosoluble carrier particles; hypolipemiant
03/13/2008US20080063725 Reservoir type, modified release of active principle; crush resistant; resists immediate dose dumping in ethanol; prevents abuse, misuse, drug addiction related behavior with stupefacients, analgesics or narcotics; microparticles coated with water-insoluble cellulose derivatives, nitrogenous copolymers
03/13/2008US20080063724 Methods and compostions for treating proliferative diseases
03/13/2008US20080063721 Sustained release microparticle; a biodegradable and biocompatible polymer; active agent risperidone, 9-hydroxy-risperidone; pharmaceutically acceptable acid addition salts; inhibiting serotonergic or dopaminergic overstimulation
03/13/2008US20080063719 Pharmaceutical Compositions
03/13/2008US20080063712 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
03/13/2008US20080063711 Controlled Release Nisoldipine Compositions
03/13/2008US20080063710 Rapidly Disintegrating Tablet and Production Method Thereof
03/13/2008US20080063709 Trisecting, quadrisecting, and a pentasecting score pattern in or on a tablet; psychotherapeutic doxepin hydrochloride; enhanced dosage flexibility
03/13/2008US20080063707 Controlled release tablet formulations for the prevention of arrhythmias
03/13/2008US20080063706 Methods and Medicaments for Administration of Ibuprofen
03/13/2008US20080063705 Solid Pharmaceutical Composition Comprising Donepezil Hydrochloride
03/13/2008US20080063704 Storage stability, waterproof; microcrystalline cellulose as diluent; magnesium stearate as lubricant; hard gelatin capsule
03/13/2008US20080063702 Liposomal Formulations Comprising an Amphipathic Weak Base Like Tempamine for Treatment of Neurodegenerative Conditions
03/13/2008US20080063701 Lipids of a liposome comprising cationic N1-cholesteryloxycarbonyl-3,7-diazanononane-1,9-diamine and/or noncationic dioleoyl phosphatidylethanolamine and short interference RNA (siRNA) are coupled, reversibly or irreversibly, to one or more polymers; drug delivery; freeze drying
03/13/2008US20080063699 Method of Administering Cationic Liposomes Comprising an Active Drug
03/13/2008US20080063698 Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use
03/13/2008US20080063696 Use of penetration enhancers and barrier disruption methods to enhance the immune response of antigen and adjuvant
03/13/2008US20080063692 Isomaltooligosaccharides to Inhibit Avian Pathogenic Intestinal Bacteria
03/13/2008US20080063690 Nut skin products
03/13/2008US20080063689 Cyanidin-3-glycoside and/or delphinium-3-glycoside; dicreatine malate, creatine citrate, creatine pyruvate, alkaline creatine, magnesium creatine chelate, creatine ethyl ester, tricreatine malate, creatine hydrates, creatine phosphate or other derivatives; enhance nutrient transport; athletic performance
03/13/2008US20080063687 Injectable sustained release delivery devices
03/13/2008US20080063682 treatment of surgical adhesions, keloid; continuously controlled release a therapeutic agent in combination with a fucoidan
03/13/2008US20080063681 Therapeutic bone replacement material
03/13/2008US20080063678 Novel 2-Cyano-3(Halo)Alkoxy-Benzenesulfonamide Compounds for Combating Animal Pests
03/13/2008US20080063673 Method and kit for treatment/prevention of hair loss
03/13/2008US20080063670 Nitroimidazole composition and method
03/13/2008US20080063669 treating fungal infections with aqueous composition free of crystals of terconazole; inhibiting the crystallization by adding citric acid; improve therapeutic release of terconazole drug
03/13/2008US20080063668 Nitroimidazole and terconazole composition and method
03/13/2008US20080063661 treating a wart with a fusion protein comprising (1) a heat shock protein and (2) a human papilloma virus (HPV) protein; Mycobacterium bovis heat shock protein; HPV is an E7 protein; cervical dysplasia, anal cancer, anal dysplasia
03/13/2008US20080063656 Adenoviral Vector Compositions
03/13/2008US20080063654 Prostate Cancer Vaccine
03/13/2008US20080063650 membrane-bound complement regulatory protein; use in enhancing the activity of antiproliferative/beta-glucan immunotherapy; mCRP antagonist; a therapeutic ligand capable of activating complement; and beta-glucan
03/13/2008US20080063642 Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders
03/13/2008US20080063640 Pin-Prc Transition Genes
03/13/2008US20080063638 Mitotic kinesin-like protein-1, MKLP1, and uses therof priority
03/13/2008US20080063626 Minimization of drug oxidation in drug irradiated excipients formulations
03/13/2008US20080063624 administering compounds which bind to the chemokine receptors, such as 1,1'-[1,4-phenylene-bis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane, optionally with colony stimulating factors, to effect regeneration of dead myocardium
03/13/2008US20080063622 Composition and Method for Delivery of BMP-2 Amplifier/Co-Activator for Enhancement of Osteogenesis
03/13/2008US20080063621 surface treated lipids encapsulating drugs, dyes, genetic engineered DNA or biological molecule of interest into liposomes or micelles, used for drug delivery, facilitating controlled release and/or tissue targeting
03/13/2008US20080063620 biodegradable amphiphillic copolymers comprising hydrophobic and hydrophillic segments, capable of undergoing transitions that results in an increase in viscosity in response to a change in temperature, used for drug delivery, prevention of surgical adhesions, as bioadhesives and in tissue engineering
03/13/2008US20080063618 a mixture of zinc pyrithione in combination with water soluble zinc containing materials such as zinc oxide and anionic, cationic, nonionic, amphoteric or zwitterionic surfactants, used as antidandruff agents with improved efficacy
03/13/2008US20080063614 Skin compositions containing hydrocortisone
03/13/2008US20080063608 Pharmaceutical Compositions for Inhalation Containing an Anticholinergic, Corticosteroid, and Betamimetic
03/13/2008US20080063606 Pulmonary delivery of aminoglycoside
03/13/2008US20080063601 treatment of urogenital disorders comprising administering calcium channel blockers, such as triptolide, prodrugs and/or derivatives
03/13/2008US20080063600 use of deactivated lymphocytes, antibodies, drug mixtures and adjuvants, for the treatment or prevention of Cruetzfield-Jacobs disease in humans or animals; immunology; bioassays
03/13/2008US20080060645 Dry Powder Inhalant Composition
03/13/2008DE112006001067T5 Dotierte Halbleiter-Nanokristalle und Verfahren zu deren Herstellung Doped semiconductor nanocrystals and methods for their preparation
03/13/2008DE10107659B4 Mucoadhäsive zerfallsfähige Arzneizubereitung zur Wirkstoffverabreichung in der Veterinär- und Humanmedizin Mucoadhesive disintegratable pharmaceutical preparation for drug delivery in veterinary and human medicine
03/13/2008CA2698597A1 Monitoring cancer stem cells
03/13/2008CA2666686A1 Inhibitors of 5-lipoxygenase activating protein (flap)
03/13/2008CA2663121A1 Treatment, prevention, and reversal of alcohol-induced brain disease
03/13/2008CA2663100A1 Indazole derivatives as modulators of interleukin-1 receptor-associated kinase
03/13/2008CA2663091A1 Modulators of interleukin-1 receptor-associated kinase
03/13/2008CA2663075A1 Substituted oxazole ketone modulators of fatty acid amide hydrolase
03/13/2008CA2663041A1 Method of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
03/13/2008CA2663003A1 Compositions and methods for enhancing transport through mucus